Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Arravinth Anantharajah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Gastrointestinal Neoplasms, Health Knowledge, Attitudes, Practice, Informed Consent. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pharmacogenetics (PGx) applies knowledge of drug‐gene interactions to maximize effectiveness and reduce toxicity of medications. PGx impacts the dosing of chemotherapy for gastrointestinal cancer, including fluoropyrimidines and irinotecan. However, pretreatment PGx testing is not routinely implemented due to barriers, including insufficient data surrounding counseling practices. This study assessed genetics knowledge and PGx attitudes in patients with gastrointestinal cancers. A survey was distributed to Penn Medicine Biobank and IMPACT‐GI participants. Multivariable analysis was conducted to assess the influence of genetics knowledge and patient characteristics on attitudes toward PGx. 132 participants completed the survey, 69 (52%) female, 22 (17%) non‐White, 50 (38%) colorectal and 40 (30%) pancreatic cancers. The mean genetics knowledge score was 2.67 ± 1.14 correct responses out of 4. Willingness to undergo pharmacogenetic testing was associated with higher genetics knowledge ( β = 0.6, 95% CI [0.1, 1.0], p = 0.0132), being female ( β = 1.1, 95% CI [0.0, 2.2], p = 0.0435), and higher self‐reported health literacy ( β = 2.2, 95% CI [0.9, 3.5], p < 0.001). Participants were less willing to undergo testing if they had health insurance concerns ( β = −3.7, 95% CI [−5.8, −1.7], p < 0.001) or did not complete secondary education ( β = −2.0, 95% CI [−3.5, −0.6], p = 0.006). Patients preferred providers to obtain consent and explain PGx's utility before testing. These findings provide initial patient‐informed guidance for the implementation of pharmacogenetic testing in gastrointestinal cancer care and identify targets for patient education. As all survey respondents were research‐engaged and from a single institution, the study population may not be widely generalizable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Translational Medicine and Human Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Victoria A Wittner, Mari Angelica S Cayabyab, Glenda Hoffecker, Sony Tuteja
Zitieren
APA
Anantharajah, A., Chaudhry, R., Wittner, V. A., Cayabyab, M. A. S., Hoffecker, G., Wang, X., Conway, L. J., Medicine Biobank, P., Teitelbaum, U. R., & Tuteja, S. (2026). Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer. Clinical and Translational Science. https://doi.org/10.1111/cts.70459
Vancouver
Anantharajah A, Chaudhry R, Wittner VA, Cayabyab MAS, Hoffecker G, Wang X, et al. Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer. Clinical and Translational Science. 2026. doi:10.1111/cts.70459
BibTeX
@article{Anantharajah2026,
author = {Anantharajah, Arravinth and Chaudhry, Raza and Wittner, Victoria A and Cayabyab, Mari Angelica S and Hoffecker, Glenda and Wang, Xingmei and Conway, Laura J and Medicine Biobank, Penn and Teitelbaum, Ursina R and Tuteja, Sony},
title = {Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70459}
}
EUVIMED